News Releases

- Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-303 phase 1 ongoing; data

- NEON-1 Data Selected for Minisymposium Oral Presentation - SEATTLE --(BUSINESS WIRE)--Mar. 8, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today

-NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- SEATTLE --(BUSINESS WIRE)--Mar. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today

SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate

SEATTLE --(BUSINESS WIRE)--Jan. 4, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at

- Horizon will have exclusive rights to develop and commercialize up to four preclinical candidates - - Horizon will make a $40 million payment at closing, consisting of a $25 million upfront cash payment and a $15 million equity investment - - Alpine eligible to receive additional payments of up

SEATTLE --(BUSINESS WIRE)--Nov. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at

- Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - SEATTLE --(BUSINESS WIRE)--Nov.

- ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - SEATTLE --(BUSINESS WIRE)--Nov. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in

SEATTLE --(BUSINESS WIRE)--Sep. 15, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase